Company | Price d* | Change d* | Volume, Avg. k, d* | Market Cap. d* | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding d* | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biotechnology Average | - - | - - | - - | 13,957.02 | 870.44 | 217.82 | -179.54 | 38.37 | 0.03 | 15.0918 | -0.33 | -95.9104 | -1,066.8587 | -9.27 | -8.64 | 747.3866 | - - | ||
Maximum | - - | - - | - - | 593,913.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.94 | 1,336.3467 | 6.70 | 300.5100 | 8,534.8500 | 38.40 | 835.37 | 6,156.2100 | - - | ||
Minimum | - - | - - | - - | 0.00 | 0.00 | -1,175.00 | -56,335.00 | -1,185.00 | 0.00 | -164.8536 | -8.99 | -10,177.5800 | -26,798.2100 | -155.91 | -1,263.79 | 0.0700 | - - | ||
DICE Therapeutics, Inc. DICE | 47.55 | 0.03 0.06% | 4,332 vs. 1,753 | 2,270.00 | 0.00 | -34.00 | -30.00 | -248.00 | -0.7400 | -15.7831 | 0.00 | 0.00 | 0.00 | -6.71 | -6.32 | 2568.58 | 47.00 | ||
Nuvalent, Inc. NUVL | 104.43 | 1.80 1.75% | 22 vs. 423 | 7,288.00 | 0.00 | -44.00 | -36.00 | -330.00 | -0.6900 | -27.7942 | 0.00 | 0.00 | 0.00 | -6.59 | -6.28 | 2069.70 | 69.00 | ||
Vaxcyte, Inc. PCVX | 119.90 | 3.36 2.88% | 92 vs. 1,024 | 14,604.00 | 0.00 | -95.00 | -171.00 | -1,019.00 | -0.8500 | -19.6094 | 0.00 | 0.00 | 0.00 | -4.79 | -4.54 | 1724.98 | 121.00 | ||
Prothena Corporation plc PRTA | 22.09 | 0.61 2.83% | 24 vs. 424 | 1,187.00 | 0.00 | -72.00 | -73.00 | -1,052.00 | -1.3400 | -4.8610 | 0.00 | -1674.00 | -144478.00 | -14.38 | -11.59 | 1263.14 | 53.00 | ||
Madrigal Pharmaceuticals, Inc. MDGL | 237.53 | 4.37 1.87% | 9 vs. 281 | 5,157.00 | 0.00 | -147.00 | -149.00 | -1,483.00 | -7.3800 | -8.6674 | 0.00 | 0.00 | 0.00 | -17.34 | -13.63 | 926.23 | 21.00 |